The European Commission and the European Investment Bank (EIB) Group have today announced an initiative to mobilise €10 billion in investment in 2026-27 into the biotech and life sciences sector. The project aims to give a significant boost to the EU’s competitiveness in biotechnology, by addressing the EU’s current investment gap and mobilising public-private investment into promising new health solutions.
Biotech can revolutionise healthcare, by delivering ground-breaking medicines and treatments to patients, such as AI-driven cardiac sensors to monitor for heart failure, mRNA therapies or monoclonal antibodies to help the immune system to spot harmful cells quickly. It is at the core of pioneering work in gene therapies, personalised medicine and biopharmaceuticals, such as synthetic insulin.